Polyclonal Antibodies Market Analysis

Polyclonal Antibodies Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is segmented into primary antibodies and secondary antibodies. The secondary antibodies segment held the largest industry share at 66.4% in 2022.
 

• The dominance of secondary antibodies in the industry can be attributed to their role in signal amplification during detection methods like ELISA, western blotting and immunohistochemistry.
   
• Further, the ability to recognize multiple epitopes on antibodies enable to enhance assay sensitivity and specificity. Similarly, the flexibility and signal amplification capability remark the secondary antibodies as a preferred choice.
   

Based on application, the polyclonal antibodies market is classified into diagnostics, therapeutics, and research. The diagnostics segment is expected to mark its dominance in 2022 accounting for the highest share of 59%.
 

• The extensive use of polyclonal antibodies in diagnostic assays, such as ELISA, immunohistochemistry, and western blotting, has driven their dominance. The antibodies detect numerous epitopes on target antigens as well as the unknow antigens due to its enhanced sensitivity and specificity that makes it suitable for diagnostic tests.
   
• Further, with a rising demand for accurate disease detection and monitoring, polyclonal antibodies play a pivotal role in various diagnostic applications.
   

Based on route of administration, the polyclonal antibodies market is classified into intravenous (IV), subcutaneous (SC), and other routes of administration. The intravenous (IV) segment is expected to exhibit CAGR of 5.3% by 2032.
 

• The popularity of intravenous administration in clinical settings, along with its convenience and established safety profile, consolidates its dominance in the market Intravenous (IV), route is preferred for several polyclonal antibody-based treatments as it allows precise dosing control and immediate systemic distribution. According to a study published in NCBI, approximately 70% of the antibodies are administered via intravenous (IV) injection, enabling rapid systemic drug delivery. And maximizing their bioavailability.
   

Based on source, the market is categorized into rabbit, goat, mouse, human and other sources. In 2022, the rabbit segment accounted for USD 826.9 million revenue.
 

• Rabbit polyclonal antibodies have been found in widespread application in biomedical research, particularly in immunological techniques like immunohistochemistry, western blotting, and flow cytometry.
   
• The preference for rabbit polyclonal antibodies was attributed due to its rapid immune response against small molecules, and post-translational modifications.
   
• These antibodies exhibit superior affinity and specificity compared to other sources, demonstrating high binding capability in the picomolar range.
   

Based on end-users, the global polyclonal antibodies market is categorized into pharmaceutical & biotechnology companies, academic and research institutes, contract research Organizations (CROs), diagnostic laboratories and other end-users. The pharmaceutical & biotechnology companies segment led the industry share with a 45.9% in 2022.
 

• Pharmaceutical & biotechnology companies are at the forefront of the industry, driven by heightened demand for these antibodies in drug discovery, development, and increased investment in biologics.
   
• Also, companies are actively collaborating with other companies and end-users to improve their R&D capabilities extending pipeline studies, investing in research to create effective products that meet therapeutic requirements.
   

In 2022, North America held a significant market share of 38.3% in the polyclonal antibodies market.
 

• North America establishes its dominance in the industry due to a confluence of factors. The region's advanced healthcare infrastructure, substantial research & development activities, and robust biotechnology industry.
   
• Moreover, the presence of key market players, strategic collaborations between academic institutions and pharmaceutical companies, and increasing investments in biomedical research further propel the business progression.